Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03566693 · ClinicalTrials.gov registry record · NA

Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)

A NA study of Diabetes Mellitus, Type 2, sponsored by DexCom.

Completed
Registry status
NA
Development phase
176
Enrollment target
15
Study locations

NCT03566693 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by DexCom. The registered enrollment target is 176 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The trial reports 15 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03566693, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by DexCom.

COMPLETED
Registry status
NA
Development phase
176 participants
Enrollment target
15
Study locations

Study Summary

A study to compare the glycemic and quality of life benefits of diabetes management using Dexcom G6 continuous glucose monitoring (CGM) or self-monitored blood glucose (SMBG) made by study participants and their primary care physicians. Decisions will be based on insights from real-time use and retrospective insights, determined during remote visits. Participants will have type 2 diabetes and be using basal insulin (with or without oral medications and/or Glucagon-Like-Peptide-1 (GLP-1) analogue) and have an elevated Hemoglobin A1C (HbA1c).

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DEVICE Blood glucose meter
  • DEVICE Dexcom G6 CGM System

Study Locations (15)

North Carolina

  • University of North Carolina - Chapel Hill
  • Carteret Medical Group - Morehead City
  • Lucas Research / Diabetes & Endocrinology Consultants, PC - Morehead City

California

  • Keck School of Medicine @ USC - Los Angeles
  • Scripps Whittier Diabetes Institute - San Diego

Michigan

  • University of Michigan Internal Medicine - Ann Arbor
  • Henry Ford Medical Center - Detroit

Georgia

  • Emory University - Atlanta

Illinois

  • Northwestern Memorial - Chicago

Iowa

  • Iowa Diabetes and Endocrinology Research Center - West Des Moines

Minnesota

  • Park Nicollet International Diabetes Center - Minneapolis

Missouri

  • Washington University Barnes Jewish Hospital - St Louis

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2018-07-30
Est. Completion 2021-01-04
Phase NA

Sponsor

DexCom

26 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03566693

The ClinicalTrials.gov registry entry for NCT03566693 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The listed sponsor is DexCom, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Blood glucose meter is the first listed.

NCT03566693 reports 15 study locations spanning 11 distinct geographic areas - top geographies include North Carolina, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT03566693 about?

NCT03566693 is a clinical study titled "Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)". A study to compare the glycemic and quality of life benefits of diabetes management using Dexcom G6 continuous glucose monitoring (CGM) or self-monitored blood glucose (SMBG) made by study participants and their primary care physicians. Decisions will be based on insights from real-time use and retr...

What is the current status of trial NCT03566693?

This trial is currently completed. It is a NA study. The enrollment target is 176 participants. The study started on 2018-07-30. Estimated completion is 2021-01-04.

What conditions does trial NCT03566693 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT03566693?

The interventions under investigation include: Blood glucose meter (DEVICE), Dexcom G6 CGM System (DEVICE).

Who is sponsoring clinical trial NCT03566693?

This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03566693 being conducted?

This trial has 15 study locations across California, Georgia, Illinois, Iowa, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 2

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.